Stoke Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Stoke Therapeutics şirketinin toplam hissedar öz sermayesi $232.1M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $293.3M ve $61.2M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$239.20m
Eşitlik	US$232.11m
Toplam yükümlülükler	US$61.21m
Toplam varlıklar	US$293.32m

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 0GT 'nin kısa vadeli varlıkları ( $253.6M ) kısa vadeli yükümlülüklerini ( $49.9M ) aşıyor.

Uzun Vadeli Yükümlülükler: 0GT şirketinin kısa vadeli varlıkları ( $253.6M ) uzun vadeli yükümlülüklerini ( $11.3M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 0GT borçsuzdur.

Borcun Azaltılması: 0GT son 5 yıldır borcu bulunmamaktadır.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: 0GT şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: 0GT serbest nakit akışı her yıl % 23.4 1.8 yıl yetecek nakit akışına sahip olacaktır.

Stoke Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

New major risk - Revenue and earnings growth

Third quarter 2024 earnings released: US$0.47 loss per share (vs US$0.55 loss in 3Q 2023)

Stoke Therapeutics, Inc. Appoints Eric Olson as Chief Business Officer

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

Second quarter 2024 earnings released: US$0.46 loss per share (vs US$0.69 loss in 2Q 2023)

First quarter 2024 earnings released: US$0.57 loss per share (vs US$0.53 loss in 1Q 2023)

Stoke Therapeutics, Inc. Announces Executive Changes, Effective May 7, 2024

Stoke Therapeutics, Inc., Annual General Meeting, Jun 05, 2024

Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer

Stoke Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $125.000004 million.

Stoke Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $125.000005 million.

Stoke Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Full year 2023 earnings released: US$2.38 loss per share (vs US$2.60 loss in FY 2022)

New major risk - Share price stability

New major risk - Share price stability

New major risk - Revenue and earnings growth

Third quarter 2023 earnings released: US$0.55 loss per share (vs US$0.66 loss in 3Q 2022)

New major risk - Revenue and earnings growth

Stoke Therapeutics, Inc. Appoints Ian Smith to Board of Directors

Stoke Therapeutics, Inc. Presents Data Related to the Ongoing Clinical Development of Stk-001 for the Treatment of Dravet Syndrome

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: US$0.69 loss per share (vs US$0.63 loss in 2Q 2022)

New major risk - Revenue and earnings growth

Stoke Therapeutics, Inc. Announces Positive New Safety & Efficacy Data from Patients Treated with STK-001 in the Phase 1/2a Studies (Monarch & Adolescents with Dravet Syndrome

Insufficient new directors

Stoke Therapeutics, Inc. Presents Data from a Combined Interim Analysis of the Phase 1/2a MONARCH and ADMIRAL Studies of STK-001 in Children and Adolescents with Dravet Syndrome at the American Epilepsy Society (AES) 2022 Annual Meeting

High number of new directors

Stoke Therapeutics Enrolls First Patient in a Natural History Study of People Living with Autosomal Dominant Optic Atrophy (ADOA)

Stoke Therapeutics, Inc.(NasdaqGS:STOK) dropped from Russell 2000 Growth Index

Stoke Therapeutics Presents New In-Vivo Data That Demonstrated Dose-Related Target Engagement and Opa1 Protein Upregulation in Retinal Tissue Following Administration of Stk-002

High number of new directors

Stoke Therapeutics Announces Positive Interim Safety, PK and CSF Exposure Data from the Phase 1/2a MONARCH Study of STK-001 in Children and Adolescents with Dravet Syndrome

Stoke Therapeutics Presents New Data That Demonstrate Tango Antisense Oligonucleotides (ASOs) Increase OPA1 Protein Production and Improve Mitochondrial Function in Cells Derived From Patients With Autosomal Dominant Optic Atrophy (ADOA)

New 90-day high: €52.50

New 90-day high: €46.00

Stoke Therapeutics Announces Presentations Related to the Company’s Work to Advance STK-001, the First Potential New Medicine to Target the Underlying Cause of Dravet Syndrome at the American Epilepsy Society (AES) 2020 Annual Meeting

Stoke Therapeutics, Inc. Announces Resignation of Robin A. Walker, Senior Vice President, Chief Legal Officer and Chief Compliance Officer

New 90-day high: €34.20

New 90-day high: €32.20

Stoke Therapeutics, Inc. Announces Plans to Move Forward with Dosing of STK-001 in Children and Adolescents in its Ongoing Phase 1/2a Monarch Study for Dravet Syndrome

New 90-day high - €26.80

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin